Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.18 USD | +2.29% | -1.58% | +1.49% |
04-29 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading | MT |
04-26 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Gets a Sell rating from Jefferies | ZD |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.49% | 12.15B | - | ||
-14.49% | 85.02B | B- | ||
+13.97% | 82.37B | C+ | ||
+10.49% | 29.29B | C+ | ||
-10.94% | 17.21B | B | ||
-0.86% | 16.7B | A- | ||
+0.63% | 15.5B | A- | ||
-2.10% | 12.13B | A- | ||
+32.15% | 12.12B | B- | ||
-31.05% | 11.8B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FME Stock
- FMS Stock
- Ratings Fresenius Medical Care AG